

Villers-lès-Nancy, 2nd July 2026 - 6:00 p.m. (CEST)

PRESS RELEASE

**RESULTS OF THE VOTES ON THE RESOLUTIONS SUBMITTED
TO THE ORDINARY ANNUAL SHAREHOLDERS' MEETING
OF 25 JUNE 2026**

Number of shares comprising the share capital: **15,174,125**

Number of shares with voting rights: **14,832,456**

Number of shares with voting rights possessed by shareholders presents or represented or having voted by mail: **13,021,748**

That means a quorum of 87.8% of the 14,832,456 shares with voting rights: the Ordinary Annual General Meeting was able to deliberate.

The Ordinary Annual General Meeting was held on Thursday, 25 June 2026 at 9:30 a.m. at the Company's headquarters and approved the separate parent company and consolidated financial statements for the 2025 financial year. The results of the votes on the resolutions proposed at this meeting by the Board of Directors were as follows:

Resolutions	Results of the votes
RESOLUTION ONE Approval of the annual financial statements	Resolution adopted by: - 13,009,592 votes in favour - 0 vote against - 12,156 abstentions
RESOLUTION TWO Discharge of directors and discharge of the Statutory Auditors for the performance of their engagement	Resolution adopted by: - 12,632,801 votes in favour - 376,685 votes against - 12,262 abstentions
RESOLUTION THREE Approval of the consolidated financial statements	Resolution adopted by: - 12,926,592 votes in favour - 83,000 votes against - 12,156 abstentions
RESOLUTION FOUR Appropriation of earnings, setting the dividend	Resolution adopted by: - 12,986,842 votes in favour - 34,906 votes against - 0 abstention
RESOLUTION FIVE Agreements and commitments governed by Articles L. 225-38 of the French Commercial Code	Resolution adopted by ^(*) : - 12,805,475 votes in favour - 205,624 votes against - 10,649 abstentions

RESOLUTION SIX Ratification of the co-optation of Ms. Sylvie ORTILLON as Director	Resolution adopted by: - 10,977,791 votes in favour - 2,043,747 votes against - 210 abstentions
RESOLUTION SEVEN Renewal of the term of office of Mr. François JACQUEL as Director	Resolution adopted by: - 10,462,191 votes in favour - 2,559,347 votes against - 210 abstentions
RESOLUTION EIGHT Renewal of the term of office of Mr. Grégoire DE ROTALIER as Director	Resolution adopted by: - 10,978,113 votes in favour - 1,925,939 votes against - 117,696 abstentions
RESOLUTION NINE Renewal of the term of office of LA COOPERATIVE WELCOOP as Director	Resolution adopted by: - 10,597,221 votes in favour - 2,424,527 votes against - 0 abstention
RESOLUTION TEN Appointment of a new Independent Director (Ms. Céline DARGENT)	Resolution adopted by: - 10,663,483 votes in favour - 2,358,265 votes against - 0 abstention
RESOLUTION ELEVEN Appointment of a new Director (Mr. Vincent MONESTEL)	Resolution adopted by: - 10,627,022 votes in favour - 2,394,726 votes against - 0 abstention
RESOLUTION TWELVE Appointment of a new Director (Mr. François-Pierre MARQUIER)	Resolution adopted by: - 11,125,492 votes in favour - 1,896,256 votes against - 0 abstention
RESOLUTION THIRTEEN Appointment of a Statutory Auditor	Resolution adopted by: - 13,011,099 votes in favour - 0 vote against - 10,649 abstentions
RESOLUTION FOURTEEN Approval of the information on the compensation of corporate officers paid in or granted for fiscal 2025 and mentioned in Article L. 22-10-9 of the French Commercial Code	Resolution adopted by: - 11,894,752 votes in favour - 1,116,247 votes against - 10,749 abstentions
RESOLUTION FIFTEEN Approval of the components of compensation paid in 2025 to Mr. Thierry CHAPUSOT, Chairman of the Board of Directors	Resolution adopted by: - 13,003,287 votes in favour - 7,712 votes against - 10,749 abstentions

RESOLUTION SIXTEEN Approval of the components of compensation paid in 2025 to Mr. Denis SUPPLISSON, Chief Executive Officer	Resolution adopted by: - 10,440,274 votes in favour - 2,570,725 votes against - 10,749 abstentions
RESOLUTION SEVENTEEN Approval of the components of compensation paid in 2025 to Mr. Grégoire DE ROTALIER, Deputy CEO	Resolution adopted by: - 10,440,390 votes in favour - 2,570,609 votes against - 10,749 abstentions
RESOLUTION EIGHTEEN Approval of the components of compensation paid in 2025 to Mr. Damien VALICON, Deputy CEO (non-Board member), until June 2, 2025	Resolution adopted by: - 10,496,918 votes in favour - 2,514,081 votes against - 10,749 abstentions
RESOLUTION NINETEEN Approval of the compensation policy for the Chairman of the Board of Directors for 2026	Resolution adopted by: - 13,003,287 votes in favour - 7,712 votes against - 10,749 abstentions
RESOLUTION TWENTY Approval of the compensation policy for the Chief Executive Officer for 2026	Resolution adopted by: - 10,601,036 votes in favour - 2,211,653 votes against - 209,059 abstentions
RESOLUTION TWENTY-ONE Approval of the compensation policy for the Deputy Chief Executive Officer(s) for 2026	Resolution adopted by: - 10,601,152 votes in favour - 2,211,537 votes against - 209,059 abstentions
RESOLUTION TWENTY-TWO Approval of the compensation policy for Directors	Resolution adopted by: - 12,931,089 votes in favour - 79,910 votes against - 10,749 abstentions
TWENTY-THIRD RESOLUTION Setting total annual compensation for Directors for 2026	Resolution adopted by: - 12,965,785 votes in favour - 45,214 votes against - 10,749 abstentions
TWENTY-FOURTH RESOLUTION Authorisation by the Company to repurchase its own shares	Resolution adopted by: - 11,364,336 votes in favour - 1,657,412 votes against - 0 abstention
TWENTY-FIFTH RESOLUTION Powers for formalities	Resolution adopted by: - 13,021,632 votes in favour - 0 vote against - 116 abstentions

(*) After deduction of excluded voting rights

Financial Calendar:

- Publication of H1 2026 revenue: 30 July 2026 (after market close)
- Publication of H1 2026 results: 28 September 2026 (before market opening)
- H1 2026 results presentation (SFAF): 28 September 2026
- Publication of Q3 2026 revenue: 28 October 2026 (after market close)

About Equasens Group

Founded over 35 years ago, Equasens Group, a leader in digital healthcare solutions, today employs over 1.500 people across Europe.

Equasens Group's specialised business applications facilitate the day-to-day work of healthcare professionals and their teams, working in private practice, collaborative medical structures or healthcare establishments. The Group also provides comprehensive support to healthcare professionals in the transformation of their profession by developing electronic equipment, digital solutions and healthcare robotics, as well as data hosting, financing and training adapted to their specific needs.

And reflecting the spirit of its tagline "Technology for a More Human Experience", the Group is a leading provider of interoperability solutions that improve coordination between healthcare professionals, their communications and data exchange resulting in better patient care and a more efficient and secure healthcare system.



Listed on Euronext Paris™ - Compartment B

*Indexes: MSCI GLOBAL SMALL CAP - GAÏA Index 2020 - CAC® SMALL and CAC® All-Tradable
Included in the Euronext Tech Leaders segment and the European Rising Tech label*



Eligible for the Deferred Settlement Service ("Service à Règlement Différé" - SRD) and equity savings accounts invested in small and mid-caps (PEA-PME).

ISIN: FR 0012882389 – Ticker Code: EQS

Get all the news about Equasens Group www.equasens.com and on [LinkedIn](#)

Investor Relations and Media Contacts

Equasens Group Investor Relations Chief Administrative and Financial Officer Frédérique Schmidt Tél. : +33 (0)3 83 15 90 67 frederique.schmidt@equasens.com	NewCap Investor Relations Thomas Grojean Louis-Victor Delouvrier Tél : +33 (0)1 44 71 94 94 equasens@newcap.eu	NewCap Financial media relations Nicolas Mérieau Tél : +33 (0)1 44 71 94 94 equasens@newcap.eu
---	---	--

Forward-looking statements

This press release contains forward-looking statements that are not guarantees of future performance and are based on current opinions, forecasts and assumptions, including, but not limited to, assumptions about Equasens' current and future strategy and the environment in which Equasens operates. These involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements, or industry results or other events, to materially differ from those expressed in or implied by such forward-looking statements. These risks and uncertainties include those detailed in Chapter 3 "Risk factors" of the Universal Registration Document filed with the French financial market authority (Autorité des Marchés Financiers or AMF) on April 29, 2025 under number D.25-0334. These forward-looking statements are valid only as of the date of this press release.